South Carolina is currently home to 1173 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Charleston, Greenville, Spartanburg and Columbia. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
NCT06937099
Recruiting
The main purpose of this study is to evaluate the efficacy and safety of mirikizumab and placebo compared with mirikizumab and concomitantly administered tirzepatide in adult participants with moderately to severely active CD and obesity, or overweight. The maximum duration of this study is up to 61 weeks.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/22/2025
Locations: Gastroenterology Associates - Patewood, Greenville, South Carolina
Conditions: Crohn's Disease, Obesity or Overweight
Register for Updates
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
NCT06937086
Recruiting
The main purpose of this study is to show whether in these individuals, treatment with both mirikizumab and tirzepatide, compared with treatment with mirikizumab and placebo, leads to decrease or disappearance of UC symptoms, and loss of at least one-tenth of the overall body weight. Participation in this study will last up to 61 weeks, including 52 weeks of treatment.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/22/2025
Locations: Gastroenterology Associates - Patewood, Greenville, South Carolina
Conditions: Ulcerative Colitis, Obesity or Overweight
Register for Updates
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD
NCT06883305
Recruiting
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
07/22/2025
Locations: Research Site, Rock Hill, South Carolina
Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Register for Updates
A Study of TAK-360 in Adults With Idiopathic Hypersomnia
NCT06812078
Recruiting
Idiopathic Hypersomnia (IH) is a condition where people feel extremely sleepy during the day, especially in the morning, even if they sleep a lot at night. They may have trouble waking up in the morning, no matter how much they sleep (sometimes more than 11 hours per day), and they can't help feeling tired, even after taking daytime naps. Because of this sleepiness, they may have trouble focusing, thinking clearly, or keeping up with daily activities. They may also have symptoms like dizziness o... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/22/2025
Locations: Takeda Site 13, Columbia, South Carolina
Conditions: Idiopathic Hypersomnia
Register for Updates
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
NCT06739122
Recruiting
The main purpose of this study is to evaluate additional dosing options for dulaglutide in pediatric participants with Type 2 Diabetes. Participation in this study will last about 8 months.
Gender:
ALL
Ages:
Between 10 years and 17 years
Trial Updated:
07/22/2025
Locations: Prisma Health Pediatric Endocrinology, Columbia, South Carolina
Conditions: Type 2 Diabetes
Register for Updates
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis.
NCT06611163
Recruiting
Phase 3 study to evaluate the efficacy and safety of subcutaneous tildrakizumab in subjects with moderate to severe genital psoriasis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: Columbia Dermatology & Aesthetics, Columbia, South Carolina
Conditions: Moderate to Severe Genital Psoriasis
Register for Updates
A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes
NCT06603571
Recruiting
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate the safety and efficacy of LY3841136 for chronic weight management alone or in combination with Tirzepatide across a wide dose range in participants with Type 2 Diabetes. Participation in the study will last about 64 weeks.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/22/2025
Locations: Tribe Clinical Research, LLC, Greenville, South Carolina
Conditions: Obesity, Overweight
Register for Updates
Switch or Quit R01
NCT06373679
Recruiting
This study evaluates whether non-cigarette tobacco products (e-cigarettes) can help smokers quit smoking as compared to traditional quit methods (nicotine replacement therapy or varenicline/Chantix). Participants in this study will be randomly assigned to one of two groups, then will have a choice between the offered products of that group. Participants in the e-cigarette group will have a choice of e-cigarette brand and flavor. Participants in the medication group will have choice between nicot... Read More
Gender:
ALL
Ages:
21 years and above
Trial Updated:
07/22/2025
Locations: Medical Univeristy of South Carolina, Charleston, South Carolina
Conditions: Cigarette Smoking, Smoking Behaviors
Register for Updates
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
NCT06292013
Recruiting
The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke. The study drug will be administered subcutaneously (SC) (under the skin). Approximately 1700 additional participants will be enrolled in an addendum to explore Lp(a) lowering with an alternative dosing schema.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: Accellacare Trident Cardiology, Charleston, South Carolina
Conditions: Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
Register for Updates
A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias
NCT06226571
Recruiting
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and clinical activity of SNDX-5613 in combination with intensive chemotherapy in participants with newly diagnosed acute myeloid leukemia (AML) harboring alterations in KMT2A, NPM1, or NUP98 genes.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/22/2025
Locations: MUSC Hollings Cancer Center (HCC), Charleston, South Carolina
Conditions: Acute Myeloid Leukemias
Register for Updates
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
NCT05514054
Recruiting
The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have already taken endocrine therapy for two to five years and must have a higher-than-average risk for their cancer to return. Study participation could last up to 10 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: St Francis Cancer Center, Greenville, South Carolina
Conditions: Breast Neoplasms
Register for Updates
A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine
NCT04616326
Recruiting
The main purpose of this study is to evaluate the efficacy and safety of galcanezumab for the preventive treatment of chronic migraine in participants 12 to 17 years of age. The primary objective is to demonstrate the superiority of galcanezumab versus placebo in the reduction of monthly migraine headache days across the 3-month double-blind treatment period.
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
07/22/2025
Locations: Coastal Pediatric Research, Charleston, South Carolina
Conditions: Chronic Migraine
Register for Updates